(Q38805552)

6 September 2017

Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy (English)

1 reference

6 September 2017

1 reference

Jia Ruan

1

1 reference

PubMed ID

27068437

6 September 2017

Peter Martin

series ordinal

2

1 reference

6 September 2017

1 June 2016

1 reference

Current hematologic malignancy reports

6 September 2017

1 reference

6 September 2017

11

1 reference

6 September 2017

3

1 reference

6 September 2017

234-240

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-016-0324-3

6 September 2017

0 references

cites work

Mantle cell lymphoma: evolving management strategies

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Treatment of older patients with mantle-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Outcome of deferred initial therapy in mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Indolent mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0324-3

p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas

21 January 2018

1 reference

12 December 2020

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network

1 reference

12 December 2020

A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease

1 reference

12 December 2020

p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis

1 reference

12 December 2020

10.1007/S11899-016-0324-3

Identifiers

DOI

1 reference

PubMed ID

27068437

Dimensions Publication ID

6 September 2017

0 references

1 reference

PubMed ID

27068437